754 related articles for article (PubMed ID: 28285684)
21. Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.
Gainor JF; Dardaei L; Yoda S; Friboulet L; Leshchiner I; Katayama R; Dagogo-Jack I; Gadgeel S; Schultz K; Singh M; Chin E; Parks M; Lee D; DiCecca RH; Lockerman E; Huynh T; Logan J; Ritterhouse LL; Le LP; Muniappan A; Digumarthy S; Channick C; Keyes C; Getz G; Dias-Santagata D; Heist RS; Lennerz J; Sequist LV; Benes CH; Iafrate AJ; Mino-Kenudson M; Engelman JA; Shaw AT
Cancer Discov; 2016 Oct; 6(10):1118-1133. PubMed ID: 27432227
[TBL] [Abstract][Full Text] [Related]
22. Anaplastic lymphoma kinase inhibitors in phase I and phase II clinical trials for non-small cell lung cancer.
Karachaliou N; Santarpia M; Gonzalez Cao M; Teixido C; Sosa AE; Berenguer J; Rodriguez Capote A; Altavilla G; Rosell R
Expert Opin Investig Drugs; 2017 Jun; 26(6):713-722. PubMed ID: 28463570
[TBL] [Abstract][Full Text] [Related]
23. Anaplastic lymphoma kinase rearrangement in lung cancer: its biological and clinical significance.
Toyokawa G; Seto T
Respir Investig; 2014 Nov; 52(6):330-8. PubMed ID: 25453376
[TBL] [Abstract][Full Text] [Related]
24. The accelerated path of ceritinib: Translating pre-clinical development into clinical efficacy.
Mok TSK; Crino L; Felip E; Salgia R; De Pas T; Tan DSW; Chow LQM
Cancer Treat Rev; 2017 Apr; 55():181-189. PubMed ID: 28427013
[TBL] [Abstract][Full Text] [Related]
25. Expanded Circulating Tumor Cells from a Patient with ALK-Positive Lung Cancer Present with EML4-ALK Rearrangement Along with Resistance Mutation and Enable Drug Sensitivity Testing: A Case Study.
Zhang Z; Shiratsuchi H; Palanisamy N; Nagrath S; Ramnath N
J Thorac Oncol; 2017 Feb; 12(2):397-402. PubMed ID: 27507192
[TBL] [Abstract][Full Text] [Related]
26. Overcoming crizotinib resistance in ALK-rearranged NSCLC with the second-generation ALK-inhibitor ceritinib.
Muller IB; De Langen AJ; Honeywell RJ; Giovannetti E; Peters GJ
Expert Rev Anticancer Ther; 2016; 16(2):147-57. PubMed ID: 26654422
[TBL] [Abstract][Full Text] [Related]
27. Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK.
Fontana D; Ceccon M; Gambacorti-Passerini C; Mologni L
Cancer Med; 2015 Jul; 4(7):953-65. PubMed ID: 25727400
[TBL] [Abstract][Full Text] [Related]
28. Lorlatinib and compound mutations in ALK+ large-cell neuroendocrine lung carcinoma: a case report.
Wiedemann C; Kazdal D; Cvetkovic J; Kunz J; Fisch D; Kirchner M; Kriegsmann M; Sültmann H; Heussel CP; Bischoff H; Thomas M; Stenzinger A; Christopoulos P
Cold Spring Harb Mol Case Stud; 2022 Oct; 8(6):. PubMed ID: 36207130
[TBL] [Abstract][Full Text] [Related]
29. Insight into resistance mechanism of anaplastic lymphoma kinase to alectinib and JH-VIII-157-02 caused by G1202R solvent front mutation.
Wang H; Wang Y; Guo W; Du B; Huang X; Wu R; Yang B; Lin X; Wu Y
Drug Des Devel Ther; 2018; 12():1183-1193. PubMed ID: 29785088
[TBL] [Abstract][Full Text] [Related]
30. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study.
Solomon BJ; Besse B; Bauer TM; Felip E; Soo RA; Camidge DR; Chiari R; Bearz A; Lin CC; Gadgeel SM; Riely GJ; Tan EH; Seto T; James LP; Clancy JS; Abbattista A; Martini JF; Chen J; Peltz G; Thurm H; Ou SI; Shaw AT
Lancet Oncol; 2018 Dec; 19(12):1654-1667. PubMed ID: 30413378
[TBL] [Abstract][Full Text] [Related]
31. Current and developing therapies for the treatment of non-small cell lung cancer with ALK abnormalities: update and perspectives for clinical practice.
Caccese M; Ferrara R; Pilotto S; Carbognin L; Grizzi G; Caliò A; Brunelli M; Cuppone F; Petraglia S; Scarpa A; Tortora G; Bria E
Expert Opin Pharmacother; 2016 Dec; 17(17):2253-2266. PubMed ID: 27682212
[TBL] [Abstract][Full Text] [Related]
32. The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models.
Zhang S; Anjum R; Squillace R; Nadworny S; Zhou T; Keats J; Ning Y; Wardwell SD; Miller D; Song Y; Eichinger L; Moran L; Huang WS; Liu S; Zou D; Wang Y; Mohemmad Q; Jang HG; Ye E; Narasimhan N; Wang F; Miret J; Zhu X; Clackson T; Dalgarno D; Shakespeare WC; Rivera VM
Clin Cancer Res; 2016 Nov; 22(22):5527-5538. PubMed ID: 27780853
[TBL] [Abstract][Full Text] [Related]
33. A Case of ALK-Rearranged Adenocarcinoma with Small Cell Carcinoma-Like Transformation and Resistance to Crizotinib.
Cha YJ; Cho BC; Kim HR; Lee HJ; Shim HS
J Thorac Oncol; 2016 May; 11(5):e55-e58. PubMed ID: 26752677
[TBL] [Abstract][Full Text] [Related]
34. Insights into brain metastasis in patients with ALK+ lung cancer: is the brain truly a sanctuary?
Toyokawa G; Seto T; Takenoyama M; Ichinose Y
Cancer Metastasis Rev; 2015 Dec; 34(4):797-805. PubMed ID: 26342831
[TBL] [Abstract][Full Text] [Related]
35. Identification of I1171N resistance mutation in ALK-positive non-small-cell lung cancer tumor sample and circulating tumor DNA.
Johnson AC; Dô P; Richard N; Dubos C; Michels JJ; Bonneau J; Gervais R
Lung Cancer; 2016 Sep; 99():38-40. PubMed ID: 27565911
[TBL] [Abstract][Full Text] [Related]
36. Transformation to small-cell lung cancer as a mechanism of acquired resistance to crizotinib and alectinib.
Miyamoto S; Ikushima S; Ono R; Awano N; Kondo K; Furuhata Y; Fukumoto K; Kumasaka T
Jpn J Clin Oncol; 2016 Feb; 46(2):170-3. PubMed ID: 26613679
[TBL] [Abstract][Full Text] [Related]
37. Second- and third-generation ALK inhibitors for non-small cell lung cancer.
Wu J; Savooji J; Liu D
J Hematol Oncol; 2016 Mar; 9():19. PubMed ID: 26951079
[TBL] [Abstract][Full Text] [Related]
38. Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial.
Shaw AT; Felip E; Bauer TM; Besse B; Navarro A; Postel-Vinay S; Gainor JF; Johnson M; Dietrich J; James LP; Clancy JS; Chen J; Martini JF; Abbattista A; Solomon BJ
Lancet Oncol; 2017 Dec; 18(12):1590-1599. PubMed ID: 29074098
[TBL] [Abstract][Full Text] [Related]
39. Treatment of ALK-Rearranged Non-Small Cell Lung Cancer: Recent Progress and Future Directions.
Cameron L; Solomon B
Drugs; 2015 Jul; 75(10):1059-70. PubMed ID: 26076736
[TBL] [Abstract][Full Text] [Related]
40. Prediction of ALK mutations mediating ALK-TKIs resistance and drug re-purposing to overcome the resistance.
Okada K; Araki M; Sakashita T; Ma B; Kanada R; Yanagitani N; Horiike A; Koike S; Oh-Hara T; Watanabe K; Tamai K; Maemondo M; Nishio M; Ishikawa T; Okuno Y; Fujita N; Katayama R
EBioMedicine; 2019 Mar; 41():105-119. PubMed ID: 30662002
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
